Scarica l'app Stockscreener
338.11
0.24%
-0.80
Dopo l'orario di chiusura:
338.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MDGL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$338.91
Aprire:
$333.48
Volume 24 ore:
346.44K
Relative Volume:
1.00
Capitalizzazione di mercato:
$7.51B
Reddito:
-
Utile/perdita netta:
$-518.67M
Rapporto P/E:
-13.46
EPS:
-25.12
Flusso di cassa netto:
$-438.32M
1 W Prestazione:
+16.64%
1M Prestazione:
+13.13%
6M Prestazione:
+2.37%
1 anno Prestazione:
+26.84%
Intervallo 1D:
$331.00
$343.17
Intervallo di 1 settimana:
$290.00
$350.00
Portata 52W:
$200.63
$377.46
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Nome
Madrigal Pharmaceuticals Inc
Settore
Industria
Telefono
404-380-9263
Indirizzo
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Confronta MDGL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
338.11 | 7.52B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.65 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.13 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.14 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.15 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.52 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-28 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-06-28 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-04-22 | Iniziato | BofA Securities | Underperform |
| 2024-03-15 | Aggiornamento | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-02-26 | Downgrade | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Reiterato | Oppenheimer | Outperform |
| 2022-12-19 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-19 | Reiterato | Piper Sandler | Overweight |
| 2022-12-19 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Ripresa | Goldman | Buy |
| 2020-11-24 | Ripresa | Evercore ISI | Outperform |
| 2020-11-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-05 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-01-30 | Iniziato | Canaccord Genuity | Buy |
| 2020-01-09 | Aggiornamento | UBS | Neutral → Buy |
| 2019-11-07 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-25 | Iniziato | Stifel | Hold |
| 2019-06-10 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-12-12 | Iniziato | B. Riley FBR | Neutral |
| 2018-11-19 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Iniziato | Citigroup | Buy |
| 2018-08-06 | Downgrade | Goldman | Buy → Neutral |
| 2018-06-28 | Iniziato | Raymond James | Mkt Perform |
Mostra tutto
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Madrigal signals blockbuster Rezdiffra trajectory as new patent extends exclusivity to 2045 - MSN
Madrigal jumps as MASH drug Rezdiffra drives massive Q2 beat - MSN
Madrigal Pharmaceuticals: Strategic Growth and Market Potential Driven by Rezdiffra’s Success and Key Acquisitions - TipRanks
Madrigal Pharmaceuticals (MDGL) Stock Target Raised on Strong 2Q Results - GuruFocus
Madrigal 2025 Q2 Earnings Strong Revenue Surge, Narrowed Losses - AInvest
Madrigal: Q2 Earnings Snapshot - New Haven Register
Madrigal Pharmaceuticals Inc (MDGL) Q2 2025 Earnings Call Highlights: Strong Sales Growth and ... By GuruFocus - Investing.com Canada
Madrigal (MDGL) Q2 Revenue Soars 1,313% - AOL.com
Madrigal Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Madrigal Surges 8.59 on 290th-Ranked $410M Volume as Patent Extensions and $212M Rezdiffra Sales Drive Momentum - AInvest
Madrigal Pharmaceuticals (MDGL) Achieves Key Growth Milestones w - GuruFocus
Madrigal Pharmaceuticals' Q2 2025: Contradictions Surrounding GLP-1 Market Impact and Rezdiffra Growth - AInvest
Madrigal Pharmaceuticals stock surges as Goldman reiterates buy on strong sales - Investing.com Canada
Madrigal Pharmaceuticals to Announce Q2 2025 Results with Live Webcast - MSN
Madrigal (MDGL) Q2 Revenue Soars 1,313% - The Motley Fool
Madrigal stock jumps after massive Q2 beat (MDGL:NASDAQ) - Seeking Alpha
Madrigal’s MASH drug handily tops forecasts as execs discuss GLP-1 combos - Endpoints News
GLP-1, Rezdiffra MASH-up eyed in $2B Madrigal/CSPC deal - BioWorld MedTech
Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Madrigal Pharmaceuticals Q2 Financial Results Exceed ExpectationsNews and Statistics - IndexBox
Madrigal Pharmaceuticals' Q2 2025 Earnings Signal a Pivotal Moment for Long-Term Value Creation - AInvest
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
China momentum continues with Madrigal-CSPC, Arrowhead- Sanofi tie-ups: Deals Report - BioCentury
How strong is Madrigal Pharmaceuticals Inc. company’s balance sheetOutstanding capital growth - Jammu Links News
Is Madrigal Pharmaceuticals Inc. stock overvalued or undervaluedInvest smarter with advanced market data - Jammu Links News
Is Madrigal Pharmaceuticals Inc. a growth stock or a value stockHigh-profit trading signals - Jammu Links News
How does Madrigal Pharmaceuticals Inc. generate profit in a changing economyAchieve triple-digit returns with smart investing - Jammu Links News
How volatile is Madrigal Pharmaceuticals Inc. stock compared to the marketBuild wealth with reliable stock picks - Jammu Links News
West Conshohocken’s Madrigal Pharmaceuticals Gets FDA Green Light - MSN
What are Madrigal Pharmaceuticals Inc. company’s key revenue driversInvest confidently with market-leading analysis - Jammu Links News
Does Madrigal Pharmaceuticals Inc. stock perform well during market downturnsSuperior trading gains - Jammu Links News
What is the dividend policy of Madrigal Pharmaceuticals Inc. stockBuild wealth faster with expert stock selection - Jammu Links News
Is Madrigal Pharmaceuticals Inc. a good long term investmentUnlock your portfolio’s hidden potential - Jammu Links News
What makes Madrigal Pharmaceuticals Inc. stock price move sharplyMaximize your returns with smart trade entries - Jammu Links News
The week in pharma: action, reaction and insight – week to August 1 - The Pharma Letter
Published on: 2025-08-03 13:27:37 - Jammu Links News
When is Madrigal Pharmaceuticals Inc. stock expected to show significant growthDiscover hidden gems in the stock market - Jammu Links News
What are analysts’ price targets for Madrigal Pharmaceuticals Inc. in the next 12 monthsExceptional risk-adjusted gains - Jammu Links News
Should I hold or sell Madrigal Pharmaceuticals Inc. stock in 2025Access daily stock market expert updates - Jammu Links News
What are the technical indicators suggesting about Madrigal Pharmaceuticals Inc.Market Forecast Opportunities Backed By Experts - Jammu Links News
Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term (MDGL) - Seeking Alpha
Madrigal in-pact with CSPC Pharma for obesity drug license - MSN
Analyzing recovery setups for Madrigal Pharmaceuticals Inc. investorsSwing Trade Entry With Volume Triggers Released - metal.it
Non-Alcoholic Steatohepatitis Market Set to Grow - openPR.com
Madrigal Pharmaceuticals Enters into Exclusive Global - GlobeNewswire
Madrigal Pharmaceuticals Secures $500 Million Credit Facility to Expand MASH Pipeline - MSN
Madrigal Pharmaceuticals' Strategic Licensing Deal: A Pivotal Move in the NASH Therapeutics Arms Race - AInvest
Madrigal inks license deal with CSPC Pharma - The Pharma Letter
Madrigal in-pact with CSPC Pharma for GLP-1 candidate license - Seeking Alpha
Madrigal Pharmaceuticals Inc Azioni (MDGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.10%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):